756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)

Jonathan W. Riess, Pilar Garrido, Tanguy Y. Seiwert et al.|Regular and Young Investigator Award Abstracts|2024

Cited by 1